Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.51 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.50 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21724700 | 1.00 | LPAR3 (0.54) | LPAR3NOD1LPAR1TLR2EPHX2 | |
| SCHEMBL21724702 | 1.00 | LPAR3 (0.54) | LPAR3NOD1LPAR1TLR2EPHX2 | |
| SCHEMBL21724489 | 1.00 | LPAR3 (0.54) | LPAR3NOD1LPAR1TLR2EPHX2 | |
| SCHEMBL27104455 | 1.00 | LPAR3 (0.54) | LPAR3NOD1LPAR1TLR2EPHX2 | |
| SCHEMBL21707446 | 0.95 | LPAR3 (0.59) | LPAR3NOD1LPAR1TLR2EPHX2 | |
| SCHEMBL24612765 | 0.90 | GRIA1 (0.58) | LPAR3LPAR1TLR2 | |
| SCHEMBL21707447 | 0.90 | LPAR3 (0.54) | LPAR3NOD1LPAR1TLR2EPHX2 | |
| SCHEMBL21724655 | 0.90 | LPAR3 (0.51) | LPAR3NOD1LPAR1TLR2EPHX2 | |
| SCHEMBL21724653 | 0.90 | LPAR3 (0.51) | LPAR3NOD1LPAR1TLR2EPHX2 | |
| SCHEMBL21732924 | 0.89 | LPAR3 (0.54) | LPAR3NOD1LPAR1TLR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11998610-B2 | Conjugates and methods of using the same | CD47, CD44, CD74 | LPAR3 2416/4885NOD1 1314/4885LPAR1 2363/4885 |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | LPAR3 2416/4885NOD1 1314/4885LPAR1 2363/4885 |
| US-20240398966-A1 | CONJUGATES AND METHODS OF USING THE SAME | CD47, CD44, CD74 | LPAR3 2416/4885NOD1 1314/4885LPAR1 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.